SEC Filings Individual Investors; Annual Reports; Annual Reports Documents; Add Files. The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies. View or download Oramed's corporate presentation. BP buys BHP US onshore assets. Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. In this section you can find more detail about our financial performance and a list of upcoming events. Events calendar for Investor Relations in Swiss Re. Email Alerts. The dividend for 2018 is an approximately 57% payout of free cash flow, reinforcing the Company's ongoing commitment to a strong dividend yield. 05 Aug 2019. Investor Presentations Green Bonds; Results as at 30 June 2018. Further information on official fuel consumption figures and the official specific CO₂ emissions of new passenger cars can be found in the EU guide 'Information on the fuel consumption, CO₂ emissions and energy consumption of new cars', which is available free of charge at. On Tuesday, 23 October 2018, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of efficacy and safety data on GSK3196165, GSK's anti-GM-CSF antibody in development for Rheumatoid Arthritis at the 2018 American College of. You can use this section to view our latest financial results and annual reports. Q4 2018 Lilly Press Release 816. June 4, 2018 05:45 PM CDT. Novartis International AG / Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden | October 19, 2018. Press Shift+? for keyboard-shortcuts. João Siffert, M. Oncology Event at ASCO 2018. Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019 February 14, 2019 Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville. Select your Region Webcasts & Presentations. 04, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. 2018 Annual Report and. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Zurich Insurance Group Ltd results and reports, including results day, results archive and letter to shareholders. About Novartis. In this section. Tecan Investor app. Basel, April 30, 2018 - Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (nAMD) from a pre-specified secondary analysis of the Phase III. 2018 Fact Book - Investor Presentation. EEO Is the Law | EEO Is the Law GINA Supplement. Group Sales for 2017 surpass 20 billion euros, performance improved and Airgas synergies are ahead of plan. Novartis International AG / Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden. Since fiscal 2018, Novartis has been focused on transforming itself into a new focused medicines company. Sanofi's financial & CSR reports include annual reports, half-year reports and integrated reports. 18, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. Since its founding almost 70 years ago, PulteGroup has delivered over 700,000 homes and today ranks as the nation’s 3rd largest homebuilding company with operations in 25 states and 47 major markets. , with 2018 sales of $11. Investors Our investor proposition. CSL is a global biotech leader. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. WALTHAM, Mass. Recent NewsSee All. Presentation: Event: End of Day Stock Quote : Enter the code shown above. Basel, June 29, 2018 — Novartis today announced its intention to spinoff Alcon, its eye care division, into a separately-traded standalone company. Basel, May 16, 2018 - Today Novartis holds its annual Meet Novartis Management event at its global headquarters in Basel, Switzerland, giving investors and analysts the opportunity to meet with key executives across the company in six separate breakout sessions. download the file 2018 Orange investor data book 3rd Quarter (Excel file) (1. The meeting provides a deeper view. Morgan Healthcare Conference Q&A session. Sanofi's financial reports, CSR and shareholder publications include annual reports, integrated reports and publications dedicated to individual shareholders. Global Sites. These disclosures are not subject to a specific framework in order to inform the users of the financial reports in a focused manner – in contrast to the disclosures in our separately available “Sustain - ability Information 2018” document, which are based on the stan -. , June 16, 2018 /PRNewswire/ -- Novartis today announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah ® (tisagenlecleucel) when administered to adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Smith announces an investigation on behalf of Novartis AG ("Novartis" or the "Company") (NYSE: NVS ) investors concerning the Company and its officers' possible violations of federal securities laws. Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer and the second on other drugs, while switching out its current pharma head in the second high. Find out more at For more information, find out more at www. Also this morning, a press release was distributed on the Capital Markets Day. footprint to prepare for commercialization in the U. Top 5% national ranking through third. We pioneer novel approaches to help people around the world access high-quality medicine. Novartis recently expanded its own global multisite Phase II clinical trial of CTL019 in pediatric r/r ALL with the opening of study sites in Europe, Canada and Australia. Samir Shah – Global Head-Investor Relations. As of June 30, 2018, we were authorized to repurchase up to $75. Novartis assumes no responsibility to update the information to reflect subsequent developments. Upstream investor day and fieldtrip - December 2018 Bernard Looney presented an update on BP’s Upstream strategy during an investor day in Oman. Elanco Animal Health Reports Strong 2018 Fourth Quarter and Full Year Results, Confirms 2019 Guidance January 30, 2019 Elanco Revises Date for Fourth Quarter 2018 Financial Results. Basel, October 19, 2018 - Novartis today announced presentation of a new analysis of Lutathera ® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden. 2018 First half results investor presentation 2. Results, reports & presentations. Media Releases. Novartis press release. Information Request. Corporate governance. Novartis AG (NVS) Q3 2018 Earnings Conference Call. By using our website you agree to our use of cookies in accordance with our cookie policy. HCCI Investor Presentation Q2 2018 1 All references to the “Company,” “we,” “our,” and “us” refer to Heritage-Crystal Clean, Inc. 07 net tax benefit. Investor Relations. 2018 Annual Report – Form 10-K. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for. Go to main content. A webcast of the presentation and question-and-answer session will be accessible live through the “Investors” section of the Company’s website, www. At the company’s Friday annual meeting—barely a week after Greek lawmakers officially opened a bribery investigation into 10 politicians. 's business for stockholders, potential investors, and financial analysts. InvestorVillage Stock message boards and discussion groups. Investors can find our latest reports, financial information and governance details here. Chicago, IL. Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. Q3 is also a manifesto of us keeping our second promise: continued strong top line momentum. Disclaimer 2 This presentation contains forward-looking statements that can be identified by terminology such as such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or by express or implied discussions regarding the potential outcome of the tender offer for the shares of AveXis Inc. Legal Notes;. Learn about our strategy, sales and results or download our investor seminar presentations. 0 billion in fiscal 2018. --(BUSINESS WIRE)--Feb. By continuing to browse this site, you give consent for cookies to be used. 's business for stockholders, potential investors, and financial analysts. Better Health, Brighter Future Newsroom Careers Investors Patients HCPs Worldwide. InvestorVillage Stock message boards and discussion groups. Corporate Governance. , the studio’s biggest year ever Investor Relations. Since its founding almost 70 years ago, PulteGroup has delivered over 700,000 homes and today ranks as the nation’s 3rd largest homebuilding company with operations in 25 states and 47 major markets. , Europe and certain Rest of World markets. In October 2018, the Group acquired CSM, a specialist provider of packaging, labelling, warehousing and distribution services, with sites in the US and Europe, and iQone, as specialist pharmaceutical company in Switzerland. Novartis shareholders will get one share of Alcon for every five Novartis shares, resulting in the. Forward-Looking Statements of Pfizer Inc. Webcasts & Presentations; Financials. Novartis AG (NYSE:NVS) Q4 2018 Earnings Conference Call January 30, 2019 8:00 AM ET Company Participants. twitter linkedin mail. After submitting your request, you will receive an activation email to the requested email address. Novartis AG 2018 Q2 - Results - Earnings Call Slides Wed, Jul. Headquartered in Dublin, Ohio, Cardinal Health, Inc. These presentations remain on the Novartis website for historical purposes only. Sanofi's financial & CSR reports include annual reports, half-year reports and integrated reports. Sanofi hosted a conference call & webcast for the financial community to present the acquisition of Bioverativ Inc. IR policy Management Board of directors Annual general meeting Annual general meeting (DK) News & Events. Headquartered in San Jose, California, Adobe is one of the largest software companies in the world, with revenue of US$9. 1 MB) Deutsch (PDF 0. Forward-Looking Statements of Pfizer Inc. Dive Insight: Novartis' takeout of Endocyte marks a remarkable return on an investment the smaller company made last year to in-license the pipeline candidate which drew Novartis' eye. WEST LAFAYETTE, Ind. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and operating results for the quarter and year ended December 31, 2017. Cargill's earnings announcement for the first quarter ended August 31, 2018, is scheduled for Thursday, September 27, 2018, at 8 a. Company Releases Company releases (DK) Webcasts & presentations Investor calendar. This website uses own and third party cookies and technologies to enhance your visit by adapting browsing to your preferences. In its fourth-quarter earnings investor presentation, Novartis has guided for core net financial expenses for its new structure, which excludes Alcon and Sandoz’s US portfolio, in fiscal 2019 to. In the News Celgene, Novartis Back $46M Series A in Next Oncology Play from Flexus Execs [via Fierce Biotech]. you can see that. The 9th International Meeting on Biotechnology BIOSPAIN 2018 starts in Seville Johnson & Johnson, Lilly, MSD and Novartis participate in the Big-Pharma presentations sessions for discussing innovation, association formulas and collaboration with other agents in the system and finding opportunities for agreements and licences Andalusia is the. Vasant Narasimhan - Global Head Drug Development and. We conduct business in over 60 countries, with major facilities in Australia, Germany, Switzerland, the United Kingdom and the United States. They help us to know a little bit about you and how you use our website, which improves the browsing experience and marketing - both for you and for others. In addition, 2018 MIP was negatively impacted by higher raw material usages and costs associated with executing on strategic capital and sales growth initiatives. Basel, May 16, 2018 - Today Novartis holds its annual Meet Novartis Management event at its global headquarters in Basel, Switzerland, giving investors and analysts the opportunity to meet with key executives across the company in six separate breakout sessions. easyJet Airline Company Limited Registered in England with Registered number 3034606; subsidiary of easyJet plc Registered in England with registered number 3959649 Registered Office: Hangar 89, London Luton Airport, Luton, Bedfordshire LU2 9PF. Cargill, a privately held company, reports its financial results on a quarterly basis. All Rights Reserved. 36th Annual J. Summary Toggle Jul 30, 2019 at 9:00 AM EDT Q4 2018 Earnings Presentation 5. Esmo 2018 – In breast cancer Novartis hopes to succeed where Roche failed Jacob Plieth Novartis’s alpelisib is hailed as the first precision therapy in breast cancer, though as with other PI3K inhibitors toxicity continues to be a worry. Presentation for investors and analysts (PDF) EN. The Investor Relations website contains information about Edwards Lifesciences Corporation's business for stockholders, potential investors, and financial analysts. Total ordinary dividends for the year were US$1. The Company has further advanced its pipeline, including proprietary and partnered programs, and established a U. Browse our financial calendar to find out about our forthcoming and previous events. We are committed to providing investors with timely and accurate information about our business strategy, expansion projects, operating performance, financial goals and objectives. 31, 2018, Mylan closed an agreement with Novartis to purchase the worldwide rights to commercialize their global cystic fibrosis products consisting of TOBI Podhaler ® and TOBI ® solution, which will further enhance Mylan’s respiratory portfolio in the U. 2nd Quarter. After submitting your request, you will receive an activation email to the requested email address. 08/14/2018//by. 50 per share, or nearly 3%, to close at $88. Here, Mr Narasimhan said Novartis was looking at a range of $1. It is with great pleasure that UCB invites you to connect to the conference call and webcast on its 2018 Full Year Financial Results on Thursday 28 February 2019 at 08. Executives. Eaton announced second quarter 2019 earnings on Tuesday, July 30, 2019, before the opening of the New York Stock Exchange. Financial reporting Presenting data in a standardized format about the company's financial position. Daiichi Sankyo, Media & Investors, Investor Relations, IR Calendar, The 9th Ordinary General Meeting of Shareholders (Plan). Novartis AG (NYSE:NVS) Q4 2018 Earnings Conference Call January 30, 2019 8:00 AM ET. Brian Gilvary, chief financial officer and Bernard Looney, chief executive, Upstream hosted a webcast on 27 July 2018 to discuss our acquisition of BHP US onshore assets. Prior to Abeona, he most recently served as Senior Vice President of U. 07 net tax benefit. Chugai Pharmaceutical Co. Our fiscal year runs June 1 through May 31. TSMC served about 465 customers and manufactured more than 9,920 products for various applications covering a variety of computer, communications and consumer electronics market segments. View chart. Total announces the third 2019 interim dividend of €0. footprint to prepare for commercialization in the U. Investor Overview Home > Investor Relations > Overview Founded in 1978, Boot Barn is the largest and fastest-growing lifestyle retail chain devoted to western and work-related footwear, apparel and accessories in the U. 8% of Group revenue) with an operating margin above Group average. Unilever is covered by various financial analysts and the consensus collection was compiled from 24th September to 2nd October 2019 Please note that the consensus numbers below are a collection of analysts' own projections and the circulation of the consensus does not provide or imply any check on. Investor Relations. Contact Us with any questions or search this site for more information. Credit Suisse management is publishing the first quarter 2018 results and presenting them to investors, analysts and the media. Happy, motivated people are key to the success of our business, so we do everything we can to make working here rewarding. We hope you find our Website a valuable tool in accessing this information. subsequent quarterly reports on Form 10-Q, copies of which may be obtained by visiting PayPal's Investor Relations website at https://investor. ever promulgated in any area of human knowledge!”. Holders of Orange’s securities can receive a hard copy of the complete audited financial statements free of charge upon request. The Investor Relations website contains information about Dish's business for stockholders, potential investors, and financial analysts. Basel, October 18, 2018 - Novartis today announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted. Novartis AG (NYSE: NVS) Q2 2019 Earnings Call Please note that during the presentation, all participants will be in listen-only mode, and the conference is being recorded. Investors Genmab A/S’s ordinary shares are listed on the NASDAQ Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Novartis BioCamp hosted top 20 graduate students in biotechnology, pharmaceutical and business fields in 3 days camp based on academic excellence, leadership, and co-curricular activities. FAQs What is the ticker symbol for Novocure? Shares of Novocure are traded on the NASDAQ Global Select Stock Market under the ticker symbol NVCR. Investor Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Norfolk Southern Corporation is a leading North American transportation provider. On February 15, 2018, Air Liquide published its 2017 Annual Results. The Investor Relations website contains information about Medtronic's business for stockholders, potential investors, and financial analysts. February 27, 2018, 8:00. Previous experiences include Business courses at the Warton Business School and scientific writing work experiences. Conferences & presentations. A leading agriculture company helping to improve global food security by enabling millions of farmers to make better use of available resources. Basel, October 19, 2018 - Novartis today announced presentation of a new analysis of Lutathera ® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden. Morgan Healthcare Conference Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as. Shareholder Services. Investors and others should note that the Company announces material financial and operational information to its investors using its Investor Relations website, press releases, SEC filings and public conference calls and webcasts. The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies. Commencing with the initial presentation of the REDUCE-IT™ results as late breaking clinical results at the American Heart Association’s 2018 scientific sessions on November 10, 2018, Amarin has sponsored numerous presentations regarding the landmark results of the REDUCE-IT study. Commercial Operations at Alexion Pharmaceuticals where he led a team of several hundred people and was responsible for $2 billion in sales across three franchises. Novartis press release. 0 billion in 2018 (2. Royalties will continue to be earned on net sales of Arzerra. Now all eyes are on the FDA's take on the. 2018 in constant currencies Credit quality • Our expectation for the coming quarters is that net losses will remain low and around the average level for 2018 Capital policy. Vasant Narasimhan - Global Head Drug Development and. Partnering Secrets to successful partnering Get in touch Business mentoring AstraZeneca Exchange Media. Building for a Sustainable Future. Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. In addition to the company’s Coca-Cola brands, our portfolio includes some of the world’s most valuable beverage brands, such as AdeS soy-based beverages, Ayataka green tea, Dasani waters, Del Valle juices and nectars, Fanta, Georgia coffee, Gold Peak teas and. With the Vonovia Investor Relations App you are always up-to-date!. NYSE: Investor Presentation (Quarterly) Stock Information. 23, 2018 /PRNewswire/ -- IDEAYA Biosciences, Inc. Information Request. Novartis AG (NYSE: NVS) Q2 2019 Earnings Call Please note that during the presentation, all participants will be in listen-only mode, and the conference is being recorded. , and its subsidiaries. Investor Presentation Page 8 Immuno-oncology therapies not as effective in highly fibrotic tumors Cancer associated fibroblasts (CAFs) oppose immunotherapies by shielding tumors from T-cells Targeting CAFs with GKT831 restores response to immunotherapies Investor Presentation Diabetic Kidney Disease (DKD) is the leading. But he did tell investors what keeps him up at night, so to speak. Tuesday, 27 March 2018. We delivered what we said we would, and built foundations for future growth. 2018 10-K 10 MB. hidden text to trigger early load of fonts ПродукцияПродукцияПродукция Продукция Các sản phẩmCác sản phẩmCác sản. Novartis International AG / Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden | October 19, 2018. Novartis Pharmaceuticals Corporation, a US affiliate of Novartis, is located in East Hanover, NJ. Thank you for joining us to discuss the transaction we announced earlier today. Today, 430,000 customers in 175 countries use Oracle technologies to seize business opportunities and solve real, tangible challenges. Poised for next growth phase, anticipated to begin in 2018; Boston, May 31, 2017 - Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving investors and analysts the opportunity to meet with 30 executives across its three divisions, R&D functions and operations. Medicine Man Technologies, Inc. About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Further information on official fuel consumption figures and the official specific CO₂ emissions of new passenger cars can be found in the EU guide 'Information on the fuel consumption, CO₂ emissions and energy consumption of new cars', which is available free of charge at. The data presentation is available under Archived Scientific Presentations on the Events & Presentations page in the Investors section of www. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. Further, Genmab’s American Depositary Shares issued under its ADR Program are listed in the United States on the Nasdaq Global Select Market under the ticker symbol GMAB. June 4, 2018 05:45 PM CDT. Investors Results & Events Centre Shareholder & Debt Info Investor Relations Team Financial News Corporate Governance Sustainability Social Responsibility Economic Responsibility Environmental Responsibility. 40 Total gross amount 3. , its subsidiaries or affiliates. Strategic Information Deutsche Bank is radically transforming its business model to become more profitable, more client focused, to drive long-term growth and to improve shareholder returns. Events & Presentations Upcoming Events. Investor Relations The 9-months 2019 results of the Kuehne + Nagel Group, including the usual financial data are now available here and on our Financial Results & Presentations page. Cornerstone OnDemand, Inc. English (PDF 0. Basel, March 6, 2018 - A new global guideline on chronic urticaria (CU) recommends Xolair ® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines[1],[2]. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information. Q3 is also a manifesto of us keeping our second promise: continued strong top line momentum. The Group serves customers in more than 180 countries and has offices in about 40 countries. Vas Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, told investors on the Q1 2017 earnings call that “we continue to be on track as well with our pegfilgrastim filing, which we expect to happen in the first part of 2018. Investor Presentation Page 8 Immuno-oncology therapies not as effective in highly fibrotic tumors Cancer associated fibroblasts (CAFs) oppose immunotherapies by shielding tumors from T-cells Targeting CAFs with GKT831 restores response to immunotherapies Investor Presentation Diabetic Kidney Disease (DKD) is the leading. Basel, October 18, 2018 - Novartis today announced that it has entered into an agreement and plan of merger with Endocyte, a US-based biopharmaceutical company focused on developing targeted. Potential risks and uncertainties include such. A slides presentation and live video/webcast will be available in due course. At the Annual General Meeting on 28 March 2019, Givaudan’s Board of Directors approved a cash dividend of CHF 60. Q3 is also a manifesto of us keeping our second promise: continued strong top line momentum. Presentation Documents. One slide bluntly categorized under the. An investor presentation from May showed the underlying logic of these moves. Morgan Healthcare Conference Q&A session. Calendar of Events. By continuing to browse this site, you give consent for cookies to be used. In addition to announcements of financial results, corporate management and the investor relations department take part in hundreds of meetings and telephone conferences, whether in France or abroad, with financial analysts and portfolio managers. Regulatory news, key figures, publications and share prices. Letter to the Investors Annual General Meeting Share Register Service ADR for U. Balbir Kelly-Bisla (Director of Investor Relations): Good morning and good afternoon everyone. Find our latest quarterly results, search all results and presentations going back to 2002, watch investor webcasts and. Career Interested in knowing more about us as an employer? What your future colleagues are thinking about? And what we would expect from you if you would join the team? G. [email protected] Full-year results 2018/19: Significant acceleration in sales and profits in the second half Stäfa (Switzerland), May 21, 2019 – Sonova Holding AG, a leading provider of hearing solutions, today reports the results for the 2018/19 financial year, with all three businesses contributing to a solid financial performance…. Samir Shah - Global Head of Investor Relations. TSMC (TWSE: 2330, NYSE: TSM) created the semiconductor Dedicated IC Foundry business model when it was founded in 1987. Good morning, and welcome to PepsiCo's Third Quarter 2018 Earnings Conference Call. On this news, Novartis' share price fell $2. Roche today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil) for the treatment of acute,. This net benefit includes the second quarter $0. Business transformation. Read or listen to the conference call. Listed on the Nasdaq Copenhagen stock exchange as one of the 25 most traded shares in terms of free floated market capitalisation, also known as the C25 index, Demant is the parent company behind the commercial successes of such world-renowned brands as Oticon, Bernafon, Sonic, Audika, Oticon Medical, MAICO, Interacoustics, Amplivox, Grason-Stadler, MedRx and Sennheiser. Health Care Information Technology Medical-Surgical Supplies and Pharmaceutical Distributor: McKesson official investor center. Basel, October 19, 2018 - Novartis today announced presentation of a new analysis of Lutathera ® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden. 05 Aug 2019. These presentations remain on the Novartis website for historical purposes only. One bond with a volume of the equivalent of 450 million euros and a maturity of three years and another bond with a volume of the equivalent of 400 million euros and a maturity of seven years were placed. August 2, 2018 Nevro Reports Second Quarter 2018 Financial Results Nevro Corp. The Company adopted the guidance for the classification and presentation of restricted cash in the statement of cash flows in the first quarter of fiscal 2019, beginning November 1, 2018, using the retrospective method. ZKB Swiss Conference November 06, 2019 Zurich, Switzerland. Basel, May 16, 2018 - Today Novartis holds its annual Meet Novartis Management event at its global headquarters in Basel, Switzerland, giving investors and analysts the opportunity to meet with. To opt-out of investor email alerts, please enter your email address in the field below and you will be removed for ALL investor email alerts that you are subscribed to. Chicago, IL. Basel, October 19, 2018 - Novartis today announced presentation of a new analysis of Lutathera ® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden. Investor Day and other presentations. After submitting your request, you will receive an activation email to the requested email address. dRx catalyzes the success of digital medicine products, services, and business models by investing in early-stage companies and leveraging networks in Pharma, Mobile/IT, and the investment community. Please not that during the presentation, all participants will be on. On February 15, 2018, Air Liquide published its 2017 Annual Results. The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts. Prior to Ortho Biotech, Ric held academic appointments as Professor in the Departments of Medicine and Oncology at the University of Calgary in Canada where he joined the faculty in 1990. View Akshay Bhargava’s profile on LinkedIn, the world's largest professional community. With our 70-plus-year heritage, we are the largest eye care device company in the world - with complementary businesses in Surgical and Vision Care. IR news, reports and services for investors and analysts. This amount will be included in Genmab's 2018 guidance which will be issued on February 21, 2018. Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting November 01, 2019 Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis. , and editor Reed Miller runs down the latest corporate restructuring news, including GE's decision to spin off GE Healthcare and Novartis giving-up on Alcon. Materials that are as of a specific date, including but not limited to press releases, presentations, blog posts and webcasts, may have been superseded by subsequent events or disclosures. Barak Palatchi was appointed Chief Operations Officer of Advanced Accelerator Applications (AAA), a Novartis company, in February of 2019 following his tenure as Chief Commercial Officer in 2018. As a result, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines), created a new world-leading Consumer Healthcare joint venture with Novartis and divested our marketed Oncology business. Current 558. Investors Company Profile Since Xencor’s founding in 1997, investors have been drawn to our remarkable scientific capabilities around monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. August 01, 2018 / 10:01 pm, CEST. Download the presentation (PDF 3. Webcasts & Presentations; Financials. Morgan Healthcare Conference Presentation Jan 08, 2018 36th Annual J. Events & Presentations Events & Presentations Investor Presentation 774. MENLO PARK, Calif. You must click the confirmation link in order to complete your unsubscription. This corresponds to an increase by 12. Investor Relations. View chart. 1 million of net equity proceeds raised from the Company's "At the Market" (ATM) agreement, $8. 50 per share, or nearly 3%, to close at $88. Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request. EEO Is the Law | EEO Is the Law GINA Supplement. I have been “managing” with data for 7+ years. Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications. Focused on the Cure. Roche today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil) for the treatment of acute,. (SGI), a leader in designing and programming biology for function, today announced J. Sanofi's financial & CSR reports include annual reports, half-year reports and integrated reports. In the News Celgene, Novartis Back $46M Series A in Next Oncology Play from Flexus Execs [via Fierce Biotech]. (NASDAQ: CSOD), a global leader in cloud-based learning, talent management and talent experience software, today announced that its Board of Directors has approved a new share repurchase program under which the Company is authorized to repurchase up to $150 million of its common stock. Share Share Two clicks for more data privacy: click here to activate the button and send your recommendation. in 2018 global box office receipts for Warner Bros. Also just for ease of use, you can go directly to Novartis to their IR section under Events, and you'll find the presentation listed there. 2018 was a year of significant foundational work as we continued repositioning AIG to deliver long-term and sustainable value. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. The topline results have been selected for a late-breaking abstract session at the 2018 American College of Rheumatology (ACR) Annual Meeting, and the poster will be presented by the study's coordinating investigator, Joan T. New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions. BP buys BHP US onshore assets. Overview Financial reporting. Latest presentations by Sanofi management at broker conferences. Q3 is also a manifesto of us keeping our second promise: continued strong top line momentum. 5 Billion, an Increase of 5 Percent, Including a 1 Percent Positive Impact from Foreign Exchange Second-Quarter 2018 GAAP EPS was $0. paypal-corp. Investor Relations: Uns liegt sehr viel daran, unsere Aktionäre und Interessenten immer aktuell und kompetent zu informieren. Craig Venter Institute (JCVI). Basel, March 6, 2018 - A new global guideline on chronic urticaria (CU) recommends Xolair ® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines[1],[2]. 9 Novartis Q2 2018 Results | July 18, 2018 | Novartis Investor Presentation FDA approved on May 17 for the preventive treatment of migraine in adults High unmet need reflected in strong patient demand and physician activation Access secured with key plans (incl. Home / Investors > Events & Presentations > Event Details Merck & Co. 859-357-3155 (Office) Send Email. You can search for filings below. Learn more and visit Chemours. 03 Oct 2019 Imperial Brands Chief Executive Officer to Step Down Download PDF Download PDF 26 Sep 2019 Pre-close Trading Update Download PDF Download PDF 25 Jul 2019 Imperial Brands PLC Diversifies Next Generation Product Portfolio to Provide Further Options for Future Growth Download PDF Download PDF 08 Jul 2019 Imperial Brands Announces Revised Capital Allocation and Dividend Policy Download. Interim dividend 1. Financial reporting Presenting data in a standardized format about the company's financial position. Morgan Healthcare Conference Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as. Charity and community Charity and community We believe that corporate responsibility involves supporting and giving back to the communities in which we operate.